Infliximab

In this article, we will discuss about Infliximab (Dosage). So, let’s get started.

Indications

Crohn’s Disease

Infliximab (REMICADE®) is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.

Infliximab (REMICADE®) is indicated for reducing the number of draining enterocutaneous and rectovaginal
fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease.

Pediatric Crohn’s Disease

Infliximab (REMICADE®) is indicated for reducing signs and symptoms and inducing and maintaining clinical
remission in pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.

Ulcerative Colitis

Infliximab (REMICADE®) is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

Pediatric Ulcerative Colitis

Infliximab (REMICADE®) is indicated for reducing signs and symptoms and inducing and maintaining clinical
remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

Rheumatoid Arthritis

Infliximab (REMICADE®), in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

Ankylosing Spondylitis

Infliximab (REMICADE®) is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Psoriatic Arthritis

Infliximab (REMICADE®) is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.

Plaque Psoriasis

Infliximab (REMICADE®) is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. Infliximab (REMICADE®) should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Dosage

Crohn’s Disease

The recommended dose of Infliximab (REMICADE®) is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active Crohn’s disease or fistulizing Crohn’s disease. For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Patients who do not respond by Week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue Infliximab (REMICADE®) in these patients.

Pediatric Crohn’s Disease

The recommended dose of Infliximab (REMICADE®) for pediatric patients 6 years and older with moderately to severely active Crohn’s disease is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks.

Ulcerative Colitis

The recommended dose of Infliximab (REMICADE®) is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adult patients with moderately to severely active ulcerative colitis.

Pediatric Ulcerative Colitis

The recommended dose of REMICADE for pediatric patients 6 years and older with moderately to severely active ulcerative colitis is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks.

Rheumatoid Arthritis

The recommended dose of REMICADE is 3 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 3 mg/kg every 8 weeks thereafter for the treatment of moderately to severely active rheumatoid arthritis. Infliximab (REMICADE®) should be given in combination with methotrexate. For patients who have an incomplete response, consideration may be given to adjusting the dose up to 10 mg/kg or treating as often as every 4 weeks bearing in mind that risk of serious infections is increased at higher doses.

Ankylosing Spondylitis

The recommended dose of Infliximab (REMICADE®) is 5 mg/kg given as an intravenous induction regimen at
0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 6 weeks thereafter for the treatment of active ankylosing spondylitis.

Psoriatic Arthritis

The recommended dose of Infliximab (REMICADE®) is 5 mg/kg given as an intravenous induction regimen at
0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of psoriatic arthritis. Infliximab (REMICADE®) can be used with or without methotrexate.

Plaque Psoriasis

The recommended dose of Infliximab (REMICADE®) is 5 mg kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of chronic severe (i.e., extensive and or disabling) plaque psoriasis.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.